New molecular entities (NMEs) finally got back into the approval action after a drought of more than a month, as the US FDA gave the nod to Sage Therapeutics Inc.'s Zulresso (brexanolone) and Jazz Pharmaceuticals PLC's Sunosi (solriamfetol) as the fourth and fifth novel approvals of 2019.
But the news for NMEs wasn't all good, as Sanofi andLexicon Pharmaceuticals Inc.'s type 1 diabetes drug Zynquista...








